What are the indications, procedural steps, device selection, antiplatelet regimen, and follow‑up recommendations for percutaneous closure of a secundum atrial septal defect?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Percutaneous Device Closure for Secundum Atrial Septal Defect

Percutaneous device closure is the preferred treatment for secundum ASDs when anatomically suitable, indicated for patients with right atrial and right ventricular enlargement with or without symptoms. 1, 2

Indications for Closure

Class I (Definitive) Indications:

  • Right atrial and RV enlargement with or without symptoms 1, 2
  • Hemodynamically significant shunt (Qp:Qs ≥1.5) with evidence of RV volume overload 1
  • Paradoxical embolism 1
  • Documented orthodeoxia-platypnea 1

Do NOT close if:

  • Severe irreversible pulmonary arterial hypertension (PAH) with no evidence of left-to-right shunt 1
  • Small ASDs (<5 mm) without RV volume overload (unless paradoxical embolism present) 1

Important caveat: Older adults require evaluation for left atrial hypertension from diastolic dysfunction before closure, as ASD closure may worsen symptoms when the left atrium can no longer decompress into the right atrium 2.

Anatomic Suitability for Device Closure

Only secundum ASDs are amenable to percutaneous closure. 1, 3

Anatomic requirements:

  • Defect diameter typically <38 mm 3, 4
  • Adequate septal rims surrounding the defect for device stability 3
  • Sufficient rims are no longer required along the entire margin—deficiencies of inferior, posterior, and superior rims can be accommodated with modern devices 3

Require surgical closure:

  • Sinus venosus defects 1, 3
  • Primum ASDs 1, 3
  • Coronary sinus defects 1, 3
  • Large septal aneurysm or multifenestrated septum (requires careful interventional cardiology consultation) 1

Device Selection

Two FDA-approved devices in the United States: 3

AMPLATZER Septal Occluder:

  • Nitinol wire mesh with Dacron fabric
  • Suitable for all secundum ASD subtypes
  • Closes defects up to 38 mm diameter
  • Self-centering with left and right atrial disks connected by waist
  • Repositionable before release
  • Major complication rate: 1.6%; overall complication rate: 7.2% 3
  • Risk of cardiac erosion/perforation (rare but potentially fatal) 3

Gore HELEX Occluder:

  • Nitinol with microporous expanded polytetrafluoroethylene
  • Suitable for small-to-moderate defects (≤18 mm)
  • Repositionable even after release
  • Wire-frame fracture incidence 5-7% (usually clinically insignificant) 3
  • No reported cardiac erosions 3

Practical consideration: Minimum weight of 15 kg offers technical advantages, though procedures can be performed in children ≥2 years 3

Procedural Steps

Imaging guidance:

  • Transesophageal echocardiography (TEE) or intracardiac echocardiography is essential for guidance and assessment 3
  • Recent data support pure transthoracic echocardiography guidance in select pediatric cases, eliminating radiation exposure 5

Procedural approach:

  • Femoral vein access
  • Balloon sizing of defect
  • Device selection (typically 1-2 mm larger than stretched diameter)
  • Sequential deployment under echocardiographic guidance
  • Confirmation of device position across all rims with no residual shunt
  • Assessment for interference with atrioventricular valves or venous structures

For multiple defects: Stage deployment carefully to avoid device entanglement; close inferior defect first, then superior 6

Antiplatelet Regimen

At time of implantation:

  • Unfractionated heparin 100 U/kg (maximum 5000 U) intravenously 7

Post-procedure:

  • Standard approach: Low-dose aspirin for 6 months 7
  • Alternative for older children/adults: Aspirin plus clopidogrel for 3-6 months, then aspirin alone to complete 6 months 7
  • Aspirin often initiated 1-several days before device implantation 7

Extended therapy: If residual shunt persists after device placement, continue thromboprophylaxis beyond 6 months due to ongoing paradoxical embolus risk 7

Follow-Up Recommendations

Immediate post-procedure:

  • Clinical and echocardiographic evaluation before discharge
  • Monitor for pericardial effusion/tamponade (can occur up to several weeks post-procedure) 1

Scheduled follow-up:

  • 3 months to 1 year: Evaluation for device migration, erosion, or complications 1
  • Serial echocardiography at 1,3,6, and 12 months to assess:
    • Device position
    • Residual shunting
    • Thrombus formation
    • Pericardial effusion
    • Pulmonary artery pressure
    • RV function 1

Annual follow-up required if: 1

  • PAH persists
  • Atrial arrhythmias develop
  • RV or LV dysfunction present
  • Coexisting valvular lesions

Emergency evaluation warranted for:

  • Chest pain or syncope (possible device erosion) 1
  • Fever, fatigue, vomiting, chest/abdominal pain (possible postpericardiotomy syndrome with tamponade) 1

Major Complications to Monitor

  • Device embolization/migration (1-3% with AMPLATZER) 3
  • Cardiac erosion/perforation with tamponade (rare but potentially fatal—unique to AMPLATZER) 3
  • Atrioventricular block 3
  • Thrombus formation 3
  • Arrhythmias 3
  • Air embolism 3

Critical point: Device erosion can present weeks after implantation and requires urgent evaluation 1. The HELEX device has not been associated with erosion but has higher wire-frame fracture rates 3.

References

Related Questions

What is the recommended management for a patient with a Doppler finding consistent with a moderate-sized ostium secundum atrial septal defect?
What ECG findings are expected after atrial septal defect (ASD) closure and what is the recommended ECG monitoring schedule?
In a 57‑year‑old diabetic female with a newly diagnosed ostium secundum atrial septal defect causing a left‑to‑right shunt and dilated right atrium and right ventricle, what clinical findings should be expected?
How should a 20-year-old female with a history of atrial septal defect (ASD) closure eight years ago who now presents with severe abdominal distension and occasional pedal edema be managed?
What is the appropriate maximum device size for closing a 12‑mm secundum atrial septal defect?
For a male patient with abdominal fasciculations and a large pannus causing functional problems, is a panniculectomy preferred over a tummy‑tuck (abdominoplasty)?
What is the recommended initial therapeutic anticoagulation for a patient 10 days post‑operative with confirmed acute deep vein thrombosis or pulmonary embolism and no active surgical site bleeding?
If saliva contacts the buccal mucosal graft during urethroplasty, does it affect graft take and how should it be managed?
What is the most appropriate initial management for a 66-year-old man who recently underwent anterior rectal resection and now has an acute deep vein thrombosis of the left popliteal vein extending to the common femoral junction?
Can hypertension cause acute encephalopathy?
What is the recommended management of a descending aortic dissection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.